DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 20-563/S-024

Eli Lilly and Company
Attention: Jeffrey L. Winn, D.D.S., R.Ph.
Associate Director, U.S. Regulatory Affairs
Lilly Corporate Center
Indianapolis, IN 46285

Dear Dr. Winn:

Please refer to your supplemental new drug application dated December 20, 1999, received December 21, 1999, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Humalog (insulin lispro [rDNA origin] injection).

We acknowledge receipt of your submissions dated June 1 and 27, November 7 and 30, and December 7, and 22, 2000, and November 15 (2), 2001, March 28, May 22, June 25, and October 10 and 22, 2002, March 26, April 9, October 3, and December 5, 2003, April 26, and May 12, 24, and 25, 2004.

Your submissions of November 15, 2001, March 26, 2003, and December 5, 2003, constituted a complete response to our December 21, 2000, May 14, 2002, and September 23, 2003, action letters, respectively.

This supplemental new drug application provides for the use of Humalog with the following external insulin pumps:

1. MiniMed Models 506, 507, and 508 using MiniMed Polyfin infusion sets, or

2. Disertronic H-TRONplus V100 insulin pump (with plastic 3.15 mL insulin reservoir), and the Disertronic D-TRON and D-TRONplus insulin pumps (with Humalog 3 mL cartridges) using Disertronic Rapid infusion sets.

We completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert, text for the patient package insert for 10 mL vial, text for the patient package insert for cartridge).

Please submit the FPL electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format – NDAs*. If you elect to submit electronically, please include a WORD copy. Alternatively, you may submit 20 paper copies of the FPL as soon as it is

available, in no case more than 30 days after it is printed. Please individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 20-563/S-024." Approval of this submission by FDA is not required before the labeling is used.

All applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred. We note that you have fulfilled the pediatric study requirement for this application.

In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to this division and two copies of both the promotional materials and the package inserts directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

We also remind you that you must submit patent information on form FDA 3542, *Patent Information Submitted Upon and After Approval of an NDA or Supplement*, within 30 days of the date of this letter as required by 21 CFR 314.53(c)(2)(ii) and 314.53(d)(2) at the address provided by 21 CFR 314.53(d)(4). The form may be obtained at http://www.fda.gov/opacom/morechoices/fdaforms/cder.html. To expedite review of this patent declaration form, we request you submit an additional copy of the form to the Center for Drug Evaluation and Research "Orange Book" staff at

Food and Drug Administration
Office of Generic Drugs, HFD-610
Orange Book Staff
7500 Standish Place
Metro Park North II
Rockville, MD 20855-2773

If you have any questions, call Julie Rhee, Regulatory Project Manager, at (301) 827-6424.

Sincerely,

{See appended electronic signature page}

David G. Orloff, M.D.
Director
Division of Metabolic
and Endocrine Drug Products, HFD-510
Office of Drug Evaluation II
Center for Drug Evaluation and Research

Enclosures:
1. Physician insert (A2.0 NL 3690 AMP)
2. INFORMATION FOR THE PATIENT VIAL (A2.0 NL 6603 AMP)
3. INFORMATION FOR THE PATIENT CARTRIDGE (A2.0 NL 9085 FSAMP)

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

David Orloff

6/2/04 02:23:38 PM